| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer
|
Sathianathen, Niranjan J.
|
|
|
2 |
6 |
p. 649-655
|
article
|
| 2 |
Comparison of Magnetic Resonance Imaging-stratified Clinical Pathways and Systematic Transrectal Ultrasound-guided Biopsy Pathway for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials
|
Woo, Sungmin
|
|
|
2 |
6 |
p. 605-616
|
article
|
| 3 |
Complications and Adverse Events of Three Magnetic Resonance Imaging–based Target Biopsy Techniques in the Diagnosis of Prostate Cancer Among Men with Prior Negative Biopsies: Results from the FUTURE Trial, a Multicentre Randomised Controlled Trial
|
Wegelin, Olivier
|
|
|
2 |
6 |
p. 617-624
|
article
|
| 4 |
Contents
|
|
|
|
2 |
6 |
p. iii-v
|
article
|
| 5 |
Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
|
Graham, Jeffrey
|
|
|
2 |
6 |
p. 643-648
|
article
|
| 6 |
Development and Validation of an Improved Pathological Nodal Staging System for Urothelial Carcinoma of the Bladder
|
Patel, Devin N.
|
|
|
2 |
6 |
p. 656-663
|
article
|
| 7 |
Editorial Board
|
|
|
|
2 |
6 |
p. i-ii
|
article
|
| 8 |
First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
|
Hahn, Andrew W.
|
|
|
2 |
6 |
p. 708-715
|
article
|
| 9 |
Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate Cancer
|
Xu, Melody J.
|
|
|
2 |
6 |
p. 685-690
|
article
|
| 10 |
Impact of Hospital Case Volume on Outcomes Following Radical Nephrectomy and Inferior Vena Cava Thrombectomy
|
Freifeld, Yuval
|
|
|
2 |
6 |
p. 691-698
|
article
|
| 11 |
Long-term Outcomes for Men in a Prostate Screening Trial with an Initial Benign Prostate Biopsy: A Population-based Cohort
|
Palmstedt, Emmeli
|
|
|
2 |
6 |
p. 716-722
|
article
|
| 12 |
Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy
|
Thang, Sue Ping
|
|
|
2 |
6 |
p. 670-676
|
article
|
| 13 |
Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial
|
Armstrong, Andrew J.
|
|
|
2 |
6 |
p. 677-684
|
article
|
| 14 |
Recurrent Ta Low-grade Non-muscle-invasive Bladder Cancer: What Are the Options?
|
Rouprêt, Morgan
|
|
|
2 |
6 |
p. 723-729
|
article
|
| 15 |
Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study
|
Procopio, Giuseppe
|
|
|
2 |
6 |
p. 699-707
|
article
|
| 16 |
What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Guidelines Panel Systematic Review
|
Veskimäe, Erik
|
|
|
2 |
6 |
p. 625-642
|
article
|
| 17 |
Who Benefits from Multiparametric Magnetic Resonance Imaging After Suspicion of Prostate Cancer?
|
Morote, Juan
|
|
|
2 |
6 |
p. 664-669
|
article
|
Journal description